The ProTarget study is a Danish investigator-initiated phase 2 clinical trial that aims to facilitate patient access to commercially available molecularly targeted anti-cancer drugs based on tumor genomic profiling.

The trial aims to investigate the safety and efficacy of these treatments, when they are used outside the labeled indication to treat patients with relevant actionable targets. By doing this, we aim to identify new predictive biomarkers for targeted treatments outside the labeled indication and provide new data and essential insights in molecular pathways involved in e.g., resistance to targeted therapies.